Amarin reported $458.89M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amarin USD 458.89M 6.03M Sep/2025
AstraZeneca USD 45.89B 1.17B Sep/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025